(FRX, ILMN, ASTX, CRWE) StockBling.com Stock Report
Forest Laboratories, Inc. (NYSE:FRX) and Almirall, S.A. (ALM.MC) reported that the U.S. Food and Drug Administration (FDA) will require a three-month extension to complete its review of the data supporting the New Drug Application (NDA) for aclidinium bromide, a new long-acting antimuscarinic for the maintenance treatment of Chronic Obstructive Pulmonary Disease (COPD).
No additional data has been requested by the agency to complete the review. FDA action is now expected by July 2012.
CRWE, Crown Equity Holdings Inc., CRWE.OB
Voice over Internet Protocol (VoIP) technology offers businesses an unbeatable proposition: streamline telecommunications while reducing total cost of ownership. VoIP integrates business communications into a single infrastructure: the data network. From small businesses to large enterprises, VoIP users report increased productivity, flexibility, and lower bills.
CRWEâs subsidiary Crown Tele Services Inc. is a provider of affordable, world class (VoIP) communications solutions .
CRWEâs Crown Tele Services recently reported that it has entered into a letter of intent with BBN Solutions.
BBN Solutions doing business as BBN Telecom provides both wholesale and retail global communication, as well as calling cards.
CRWE offers advertising branding and marketing services as a worldwide online multi-media publisher with its digital network of websites and focuses on the distribution of information for the purpose of bringing together a targeted audience and the advertisers that want to reach them.
CRWEâs advertising services cover and connect a range of marketing specialties, as well as provide search engine optimization for clients interested in online media awareness.
More about CRWE at www.crownequityholdings.com.
Illumina, Inc. (NASDAQ:ILMN), a leading developer, manufacturer and marketer of life science tools and integrated systems for the analysis of genetic variation and function, recommended that its stockholders take no action at this time in response to Rocheâs announcement that it is now offering to acquire Illumina for $51.00 per share in cash.
Astex Pharmaceuticals, Inc. (NASDAQ:ASTX), a pharmaceutical company dedicated to the discovery and development of novel small molecule therapeutics, reported the acceptance of fourteen abstracts for presentation at the American Association for Cancer Research (AACR) 2012 Annual Meeting. Oral and poster presentations will occur on March 31, April 1-3 in Chicago, IL.
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. stockbling.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://stockbling.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold stockbling.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a media-advertisement and newswire company. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period.